|
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial. |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics |
| |
Ahmed Mohammed Fouad Abdelaziz |
Employment - Arizona Oncology; Tenet Healthcare |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; squibb; Takeda |
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Takeda |
| |
|
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Leadership - Next Oncology (Inst) |
Stock and Other Ownership Interests - Lilly |
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst) |
| |
|
No Relationships to Disclose |
| |
|
|
|
Travel, Accommodations, Expenses - NeoTX |
| |
|
|
|
Travel, Accommodations, Expenses - NeoX |
| |
|
|
|
Stock and Other Ownership Interests - NeoTX |
|
Consulting or Advisory Role - Indena |
Speakers' Bureau - Indena |
Patents, Royalties, Other Intellectual Property - NeoTX |
Travel, Accommodations, Expenses - NeoTX |
Other Relationship - CryptoMedix |
| |
|
|
Leadership - NeoTX; Ryvu Therapeutics |
Stock and Other Ownership Interests - Bayer; Bayer; NeoTX; Vertex |
Honoraria - Dark Blue; Ryvu Therapeutics |
Consulting or Advisory Role - Dark Blue; Ryvu Therapeutics |
|
Travel, Accommodations, Expenses - NeoTX |